Pathomic immune biomarkers define recurrence risk in early-stage melanoma.

ABSTRACT:

Background

There is an urgent need for biomarkers in early-stage melanoma because the benefit of adjuvant immunotherapy is marginal while the toxicity is considerable. Immune surveillance is a key mechanism limiting melanoma progression, but no immune biomarkers have yet been sufficiently validated for clinical use.

Methods

We validate 3 digital pathology biomarkers, all previously trained in published cohorts and testable in formalin fixed paraffin embedded specimens, for correlation with recurrence free survival and distant metastatic free survival: (1) tumor infiltrating lymphocytes identified using artificial intelligence in digital images (eTILs), (2) nanoString melanoma immune profile (MIP), and (3) quantitative immunofluorescence of CD8+ cells.

Results

Three im

SUBMITTER: Aung TN 

PROVIDER: S-EPMC12573246 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature